Physician profile
Claude Resil
NPI 1639150592
$24,332.50
in general payments reported to CMS, 2019-2025
38 companies · $2,365 in 2025
The $2,365 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,055 · 2020: $1,217 · 2021: $2,711 · 2022: $3,167 · 2023: $8,890 · 2024: $2,929 · 2025: $2,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,759 · Consulting Fee: $4,008 · Travel and Lodging: $1,386 · Education: $29.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,759.38 |
| Consulting Fee | $4,008.00 |
| Travel and Lodging | $1,386.45 |
| Education | $29.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $6,822.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $5,216.70 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,040.46 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,603.24 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $1,443.47 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $1,032.28 | 2019-2023 | |
| Lilly USA, LLC | $827.61 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $787.50 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $644.83 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $626.67 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $503.35 | 2019-2024 | Verquvo, Gardasil 9, M-M-R II |
| Pfizer INC. | $355.88 | 2019-2025 | |
| Medtronic, INC. | $308.74 | 2022-2025 | Minimed 780g |
| Amarin Pharma, INC. | $279.41 | 2019-2020 | |
| Amgen INC. | $277.85 | 2019-2024 | Repatha |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claude Resil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.